Home Investor Relations Committee Composition

Print

Email

Committee Composition

= Chair

= Member

Financial Expert

= Financial Expert

	Audit	Nominating and Governance	Compensation
R. Gordon Douglas, M.D.
Chairman of the Board R. Gordon Douglas, M.D. has been a director since our inception. Dr. Douglas currently serves as a consultant to the Vaccine Research Center at the National Institute of Health. Dr. Douglas also serves on the board of directors of Vical Incorporated. Dr. Douglas was president of Merck Vaccines from 1989 until 1999, and was responsible for the research, development, manufacturing and marketing of Merck Vaccines' vaccine products. From 1982 to 1990, he was a professor of medicine and chairman of the department of medicine at Cornell University Medical College, as well as, physician-in-chief of the New York Hospital. He also served as head of the infectious disease unit at the University of Rochester School of Medicine. Dr. Douglas is a graduate of Princeton University and Cornell University Medical College. Dr. Douglas was elected to serve on our board of directors pursuant to a stockholders' agreement between us and holders of our preferred stock. Dr. Douglas currently serves as a member of our Audit Committee.
John S. Thievon
President and Chief Executive Officer John Thievon has served as President & Chief Executive Officer and a Director on our board since September 2008. Prior to joining MiddleBrook, he was with Adams Respiratory Therapeutics, Inc. for 9 years. He held various positions there. From May 2005 through February 2008, John was an Executive Vice President with Adams. He oversaw sales operations and the field sales team, corporate accounts, business development and commercial operations, among other things. John was Vice President of Sales and Professional Marketing from May 2000 to May 2005 where he wrote the marketing plan for the launch of Mucinex®. Before that John also worked in the positions of Northeast Regional Business Director and Director of Marketing with Adams. John worked for IMS Health Inc., from January 1995 to December 1998. At IMS he worked in several positions including Account Manager, Account Director, and Director of Sales Training. He was a Sales Representative with Ortho Pharmaceuticals, Inc. from 1990 to 1994. Since November 2007, John has been a member of DaySpring Pharma, LLC's Board of Directors. DaySpring is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription and non-prescription products for specialty markets in women's health and pediatrics. John graduated from Pace University with a Bachelor of Business Administration degree, with a concentration in marketing.
Lord James Blyth
Vice Chairman Lord James Blyth of Rowington joined our board as vice chairman in October 2008. Lord James Blyth was chairman of Diageo plc from July 2000 through June 2008. Previously, he served as a non-executive director at Diageo plc since January 1999. He was formerly chief executive and then chairman of The Boots Company PLC. Lord James Blyth has held several leadership roles, including chief executive of the Plessey Company and head of defense sales at the United Kingdom Ministry of Defense. He is also a non-executive director of Anixter Inc. in the U.S. and a senior adviser to Greenhill & Co Inc., where he was previously a vice chairman. Lord James Blyth currently serves as Chairman of our Nominating and Governance Committee, as well as, our Compensation Committee.
James H. Cavanaugh, Ph.D.
Director James H. Cavanaugh, Ph.D. has been a director since our inception and has been a Managing Director of HealthCare Ventures LLC since 1989. Dr. Cavanaugh served as President of SmithKine and French Laboratories U.S., Inc., from March 1985 to February 1989 and as President of SmithKline Clinical Laboratories from 1981 to 1985. Prior thereto, Dr. Cavanaugh was the President of Allergan International, a specialty eye care company. Prior to industry experience, Dr. Cavanaugh was Deputy Assistant to the President for Domestic Affairs and Deputy Chief of the White House Staff. Before his White House tour, he served as Deputy Assistant Secretary for Health and Scientific Affairs in the U.S. Department of Health, Education and Welfare and as Special Assistant to the Surgeon General of the U.S. Public Health Service. He was a Founding Director of the Marine National Bank in Santa Ana, California. Dr. Cavanaugh holds a Doctorate and a Master's degree from the University of Iowa and a Bachelor of Science degree from Fairleigh Dickinson University. In addition to serving on the board of directors of several privately held health care and biotechnology companies, he has previously served on the Board of Directors of the National Venture Capital Association, the Pharmaceutical Research and Manufacturers Association , Unihealth America, the Proprietary Association, the Board of Trustees of the National Center for Genome Research and Trustee Emeritus of the California College of Medicine. He was non-executive Chairman of Shire Pharmaceuticals Group plc from 1999 to 2008. Dr. Cavanaugh currently serves as a member of the board of PharmAthene, Inc. and Verenium Corporation (Chairman).
Richard W. Dugan
Director Richard W. Dugan joined our board of directors in September 2003. From 1976 to 2002, Mr. Dugan served as a partner for Ernst & Young LLP, where he served in various managing and senior partner positions including mid-atlantic area senior partner from 2001 to 2002, mid-atlantic area managing partner from 1989 to 2001 and Pittsburgh office managing partner from 1981 to 1989. Mr. Dugan retired in 2002. Mr. Dugan received a B.S.B.A. from Pennsylvania State University. Mr. Dugan currently serves as the chairman of our Audit Committee.
Harold R. Werner
Director Harold R. Werner has been a director since our inception. Mr. Werner is a co-founder and general partner of HealthCare Ventures, a venture capital fund specializing in the health care industry. Mr. Werner has served as a director of over 30 public and private companies. Prior to the formation of HealthCare Ventures in 1985, Mr. Werner was Director of New Ventures for Johnson & Johnson Development Corporation. Before joining Johnson & Johnson in 1980, Mr. Werner was senior vice president of Robert S. First, Inc. and was responsible for managing its European and, later, U.S. health care management consulting business. Mr. Werner currently serves on the Board of Directors of TetraLogic Pharmaceuticals Corporation, InfaCare Pharmaceutical Corporation, DecImmune, Inc., Aciex, Inc., Oriel Therapeutics, Inc., Promedior, Inc., Xencor, Inc., and Stemgent, Inc. Mr. Werner received his B.S. and M.S. degrees from Princeton University and an M.B.A. from the Harvard Graduate School of Business Administration. Mr. Werner is currently a member of our Nominating and Governance Committee. His term as a director will expire at the 2010 Annual Meeting of Stockholders.
Martin A. Vogelbaum
Director Martin A. Vogelbaum was appointed a director in April 2007. Mr. Vogelbaum has been a partner with Rho Ventures since 2005. Prior to joining Rho, he was a general partner of Apple Tree Partners, a life sciences venture capital firm. Previously, he was a general partner of Oxford Bioscience Partners, which he joined in 1993. Mr. Vogelbaum currently serves on the Board of Directors of several privately-held companies. Mr. Vogelbaum received an A.B. in biology and history from Columbia University. Mr. Vogelbaum currently serves as a member of our Compensation Committee.
William Pate
Director William C. Pate has served as a director since September 2008. Mr. Pate also serves as a director of Covanta Holding Corporation, an energy-from-waste company, and is a member of the company's audit, finance and technology committees. He serves as a director of Exterran Holdings, Inc., a global oilfield services provider and is a member of the audit and compensation committees for Exterran. Mr. Pate also serves as a director of Tribune Company. He is managing director of Equity Group Investments, L.L.C. (EGI,) a privately-held investment firm. Mr. Pate has been employed by EGI or its predecessor in various capacities since 1994. He received a juris doctorate degree from the University of Chicago Law School and a Bachelor of Arts degree from Harvard College. Mr. Pate currently serves as a member of our Audit Committee.
Mark Sotir
Director Mark Sotir has served as a director of MiddleBrook since September 2008. He is currently the managing director for Equity Group Investments, and has held that position since 2006. He manages a number of EGI's investments, including Starwood Hotels (NYSE: HOT), and serves on the boards of directors of several portfolio companies, including: SIRVA, a moving and relocation company; WRS Holding Company, an environmental remediation company; VIA Wines Group, a Chilean wine producer and marketer; and Rewards Network, a frequent dining program for restaurants. He also recently served as the interim president of Tribune Interactive, a division of Tribune Company, a Chicago-based media conglomerate. Mr. Sotir has extensive operational restructuring experience, including merger integration, across a wide range of industries. Before joining EGI, Mr. Sotir was the Chief Executive Officer of Sunburst Technology Corporation, the leading independent distributor of educational software to public schools in the United States. He also served as the President of Budget Group, Inc. (Budget Rent a Car and Ryder Truck Rental), managing this $3 billion company with more than 13,000 employees in 120 countries through a consolidation of seven businesses. Mr. Sotir's broad-based career has also included brand management and sales roles at The Coca-Cola Company, where he managed the $800 million Minute Maid orange juice business. Mr. Sotir holds a M.B.A. from Harvard Business School and a B.A. in economics from Amherst College. Mr. Sotir currently serves as a member of our Compensation Committee.